Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 49Breast Neoplasms 47Neoplasms 39Leukemia, Lymphocytic, Chronic, B-Cell 37Carcinoma, Non-Small-Cell Lung 36Neoplasm Metastasis 29Lymphoma, Large B-Cell, Diffuse 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Brain Neoplasms 24Lymphoma, Follicular 23Lung Neoplasms 23Colonic Neoplasms 23Rectal Neoplasms 22Carcinoma, Renal Cell 22Lymphoma, Non-Hodgkin 21Prostatic Neoplasms 20Glioblastoma 20Leukemia, Myeloid, Acute 19Kidney Neoplasms 19Pancreatic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 18Lymphoma, Mantle-Cell 17Gliosarcoma 17Burkitt Lymphoma 17Sarcoma 16Multiple Myeloma 16Waldenstrom Macroglobulinemia 15Ovarian Neoplasms 15Esophageal Neoplasms 15Lymphoma 14

Interventions

ganitumab 1Receptor Protein-Tyrosine Kinases 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NIH × Rhabdomyosarcoma, Alveolar × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡